A clear view for greater reliability
For almost 30 years, scientists working with immunoassays have been aware of problems like matrix effects, cross-reactivities, high background and unspecific binding that affect the quality of results obtained with ELISAs, Western blots or protein microarrays. Such distortions mean that the validation of results is both time-consuming and costly. This might now be a problem of the past. The biotech company CANDOR Bioscience seems to have solved this problem at the same time as closing a gap in the market.
This problem solver has a name – LowCross Buffer – and it can be used for all kinds of immunoassays. The buffer dilutes antibodies and is the first reagent that can effectively reduce the problems usually experienced with ELISAs, Western blots or protein arrays. The buffer has become very popular with clients in diagnostics, pharmaceutical and basic research. CANDOR Bioscience has thus entered a market where no similar product exists.
From applied research to the business world
CANDOR Bioscience currently has 5 employees. The company was founded in Münster in 2004 by Peter Rauch and Tobias Polifke. Back then, both Rauch and Polifke were working on the improvement of this bioanalytic method at an applied research institute. When the institute was shut down, the two researchers joined forces with Angela Zellmer, the former head of laboratory at the same institute.
All the staff at CANDOR Bioscience have specific skills that make the company what it is: Peter Rauch is the development manager and contact person for all technological questions, Tobias Polifke has a background in economics and is in charge of quality management issues, Sabine Glöggler is a biologist with experience in technology transfer issues, patent application and marketing and Angela Zellmer has comprehensive experience in laboratory management.

Dr. Peter Rauch, Dr. Sabine Glöggler, Dr. Tobias Polifke and Angela Zellmer. (© Candor Bioscience)
Weak bindings are a thing of the past
Cross-reactivities and unspecific binding cannot be entirely avoided, not even by people who are extremely skilled in carrying out experiments. Such distortions often occur in assays involving blood, serum or tissue samples. It means that molecules only attach to each other weakly or moderately, with low or medium affinity to use the scientific term. The real signal caused by the binding of the antibody is very strong.
The LowCross Buffer eliminates weak binding, reduces cross-reactivity, interferences and matrix effects and leads to better measurement results, which are consequently more reliable, thus reducing the risk of obtaining false-positive and false-negative results. This in turn reduces the time required for the development of assays and validation becomes a lot more efficient.

Immunoassay without LowCross Buffer (© Candor Bioscience)

Immunoassay with LowCross Buffer. (Photos: Candor Bioscience) (© Candor Bioscience)
Signs point towards expansion

ELISA test with buffers. (© Candor Bioscience)
CANDOR Bioscience also produces a blocking solution which reduces the background by blocking free binding sites on plastic surfaces, membranes or other protein-binding surfaces. Apart from developing proprietary products, CANDOR Bioscience also develops assays and ELISAs for pharmaceutical and diagnostic companies. The service business, which has been a dependable source of revenue since the establishment of the company in 2004, has now been reduced in size, leaving more space for the development of own products.
In mid 2006, the company moved from Westphalia to Weißensberg, close to Lindau on Lake Constance, where it has larger company premises to cater for growing demand and to provide space for expansion plans. A silent partnership has given CANDOR Bioscience the means to expand its sales network to non-German speaking European countries before it turns its attention to targeting the American and Asian markets.
Production capacity can easily be expanded to up to 60,000 litres per year. Polifke explains that the company’s reagents recipe is mixed with chemicals synthesised by the company’s suppliers.
More products in future
CANDOR Bioscience, which hopes to expand its workforce to 12 employees within the next five years, also intends to considerably expand its product portfolio in the near future, in particular in order to be able to serve clients from basic pharmaceutical and medical research in addition to its clients from the diagnostic industry. In order to maintain product quality, the company will continue to produce in Germany. The company however excludes the possibility of producing own diagnostic products.
Why is the company called CANDOR? The word CANDOR in Latin refers to a particularly bright white colour. This might refer to the company’s optimised immunoassays or to the future prospects of the young company.
wp, 27 March 2007
(c) BIOPRO Baden-Württemberg GmbH